SYRSSyros Pharmaceuticals, Inc.

Nasdaq syros.com


$ 5.22 $ -0.24 (-4.41 %)    

Thursday, 02-May-2024 15:59:53 EDT
QQQ $ 429.07 $ 5.38 (1.28 %)
DIA $ 382.31 $ 3.34 (0.88 %)
SPY $ 505.01 $ 4.68 (0.94 %)
TLT $ 88.87 $ 0.38 (0.43 %)
GLD $ 213.12 $ -0.66 (-0.31 %)
$ 5.2
$ 5.34
$ 0.00 x 0
$ 0.00 x 0
$ 5.19 - $ 5.58
$ 2.09 - $ 8.17
301,209
na
147.29M
$ 0.94
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-27-2024 12-31-2023 10-K
2 11-14-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-10-2023 03-31-2023 10-Q
5 03-02-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-09-2022 06-30-2022 10-Q
8 05-16-2022 03-31-2022 10-Q
9 03-15-2022 12-31-2021 10-K
10 11-05-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-06-2021 03-31-2021 10-Q
13 03-04-2021 12-31-2020 10-K
14 11-05-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 03-05-2020 12-31-2019 10-K
18 11-12-2019 09-30-2019 10-Q
19 08-01-2019 06-30-2019 10-Q
20 05-01-2019 03-31-2019 10-Q
21 03-07-2019 12-31-2018 10-K
22 11-01-2018 09-30-2018 10-Q
23 08-07-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 03-12-2018 12-31-2017 10-K
26 11-08-2017 09-30-2017 10-Q
27 08-09-2017 06-30-2017 10-Q
28 05-15-2017 03-31-2017 10-Q
29 03-20-2017 12-31-2016 10-K
30 11-14-2016 09-30-2016 10-Q
31 08-15-2016 06-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 crude-oil-down-over-1-cognyte-software-shares-plummet

U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.4% on Tuesday. The Dow traded down 0...

 why-tilray-brands-shares-are-trading-lower-by-around-22-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter esti...

 piper-sandler-reiterates-overweight-on-syros-pharmaceuticals-maintains-13-price-target

Piper Sandler analyst Edward Tenthoff reiterates Syros Pharmaceuticals (NASDAQ:SYRS) with a Overweight and maintains $13 pri...

 top-3-health-care-stocks-youll-regret-missing-this-month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

 hc-wainwright--co-reiterates-buy-on-syros-pharmaceuticals-maintains-15-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Syros Pharmaceuticals (NASDAQ:SYRS) with a Buy and maintains $15 pric...

 syros-pharmaceuticals-q4-eps-222-misses-114-estimate-sales-38600k-miss-200m-estimate

Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(2.22) per share which missed the analyst consensus estimate ...

 earnings-scheduled-for-march-27-2024

Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on rev...

 syros-announces-completion-of-enrollment-of-190-patients-necessary-to-support-primary-endpoint-analysis-in-select-mds-1-phase-3-trial

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline...

 syros-highlights-anticipated-2024-milestones-for-tamibarotene

-- On-Track to Complete Enrollment of 190 patients for Primary Analysis in SELECT-MDS-1 Phase 3 Trial in 1Q 2024; Pivotal CR ...

 why-is-blood-cancer-focused-syros-pharmaceuticals-stock-soaring-today

Syros Pharmaceuticals Inc (NASDAQ: SYRS) released initial data from its ongoing SELECT-AML-1 Phase 2 trial of tamibarotene in c...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION